Affiliation:
1. School of Medicine, Keio University , Tokyo 160-8582 , Japan
2. Department of AI Systems Medicine, M&D Data Science Center, Tokyo Medical and Dental University , Tokyo 113-8510 , Japan
Abstract
Abstract
Immune checkpoint inhibitors, especially PD-1/PD-L1 blockade, have revolutionized cancer treatment and brought tremendous benefits to patients who otherwise would have had a limited prognosis. Nonetheless, only a small fraction of patients respond to immunotherapy, and the costs and side effects of immune checkpoint inhibitors cannot be ignored. With the advent of machine and deep learning, clinical and genetic data have been used to stratify patient responses to immunotherapy. Unfortunately, these approaches have typically been “black-box” methods that are unable to explain their predictions, thereby hindering their responsible clinical application. Herein, we developed a “white-box” Bayesian network model that achieves accurate and interpretable predictions of immunotherapy responses against nonsmall cell lung cancer (NSCLC). This tree-augmented naïve Bayes (TAN) model accurately predicted durable clinical benefits and distinguished two clinically significant subgroups with distinct prognoses. Furthermore, our state-of-the-art white-box TAN approach achieved greater accuracy than previous methods. We hope that our model will guide clinicians in selecting NSCLC patients who truly require immunotherapy and expect our approach to be easily applied to other types of cancer.
Funder
JSPS
Fukuda Foundation for Medical Technology
Publisher
Oxford University Press (OUP)
Reference64 articles.
1. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US;Ganti;JAMA Oncol,2021
2. Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment;Duma;Mayo Clin Proc,2019
3. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications;Zhang;Cell Mol Immunol,2020
4. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC);Brahmer;J Immunother Cancer,2018
5. PD-L1 expression in lung cancer;Yu;J Thorac Oncol,2016